Pfizer has begun clinical trials of the anti-virus drug, slowing the development of the virus in the body of the patient and increasing the chances of the cure. About this on Monday, April 26, Telegraph British Edition reported.
The drug should affect coronavirus, destroying its structure and preventing the proliferation of infection in the nasopharynk and light patient. The preparation presented for tests in the form of tablets includes the PF 07321332 molecule, created by scientists Pfizer.
The publication states that numerous volunteers aged from 18 to 60 years of age are involved in the tests.